Compare SPDR Gold Trust (GLD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Vertex Pharmaceuticals Incorporated — how do they compare? SPDR Gold Trust trades at $384.58 (market cap $139.66B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: SPDR Gold Trust and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 74 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GLD | VRTX | |
|---|---|---|
Market Cap | $139.66B | $127.55B |
Volume | 9,544,773 | 1,487,944 |
52-Week High | $495.90 | $557.96 |
52-Week Low | $362.32 | $407.37 |
Typical Hold Time | 74 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD trades at $378.67, up 0.74% with bearish technical signals dominating as 17 indicators signal sell versus 2 buy signals. The stock faces resistance at $380-$384 while finding support at $377-$373. Recent news highlights pressure from rising Treasury yields and dollar strength overwhelming safe-haven demand, with gold failing to sustain gains despite weak employment data.
The outlook remains cautious with technical indicators signaling bearish momentum and fundamental data unavailable. Key risks include persistent rate hike expectations and dollar strength, though some analysts see tactical buying opportunities. Investors should monitor Fed policy decisions and inflation trends for directional catalysts.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
